Partnership Focused on Antibody Development
Abzena and Mabqi are excited to announce their strategic alliance aimed at revolutionizing the process of antibody development for biopharma clients. The collaboration brings together Abzena, renowned for its integrated CDMO services, and Mabqi, a leader in biotechnology specializing in human antibodies, to create a streamlined process from discovery to development.
Streamlining Drug Development
This partnership offers an innovative approach by bridging the gap between initial discovery and subsequent pre-clinical development phases. Many drug developers face challenges in navigating the early stages of creating new therapies. By combining their expertise, Abzena and Mabqi promise to alleviate these hurdles, ensuring a smoother transition into the clinical phase.
Integrated Services to Enhance Efficiency
Working together, the two companies will utilize Mabqi's advanced LiteMab Antibody Discovery Studio, which incorporates proprietary libraries for hit screening and selection. This cutting-edge tool, combined with Abzena's robust capabilities in developability, cell line development, and GMP manufacturing, will provide clients with a comprehensive suite of services tailored to their specific needs.
Accelerated Timelines for Drug Development
Clients can expect faster timelines due to the collaboration’s emphasis on scientific excellence and innovation. The teams from both companies are dedicated to leveraging integrated data, which helps mitigate risks early in the development process. This results in a quicker path for potential therapies to reach the market, ultimately benefiting patients waiting for new treatment options.
Expertise in Biologics
Mabqi and Abzena's alliance draws on extensive knowledge across a range of modalities, including monoclonal antibodies, mAb fragments, and bioconjugates. This versatile expertise ensures they can meet the demands of various projects, helping biopharma companies advance their unique molecules efficiently.
Leadership Insights on the Partnership
According to Campbell Bunce, the Chief Scientific Officer at Abzena, this partnership signifies a powerful union of scientific capability and innovation. “By combining our strengths, we can significantly enhance our customers' programs. Our collaborative efforts enable a data-driven approach to development, highlighting our commitment to both efficiency and successful outcomes.”
Mabqi's CEO, Sylvain Yon, echoed similar sentiments, stating, “We believe this partnership will create a milestone in the biopharmaceutical industry. The synergy between our teams is vital for driving innovation and sharing our passion for delivering high-quality, impactful therapeutic antibodies for patients globally.”
About Abzena
Abzena stands out in the biopharmaceutical landscape as a leading provider of end-to-end complex biologics solutions. Dedicated to supporting clients through every phase of drug development, Abzena offers tailored programs aimed at minimizing risks and enhancing the efficiency of bringing new therapies to the marketplace. The firm maintains advanced research and cGMP facilities across several locations, empowering partners to maximize their innovations for patient benefit.
About Mabqi
Mabqi specializes in uncovering innovative human antibodies using a state-of-the-art platform. The focus on monoclonal antibodies and antibody-drug conjugates positions Mabqi as a key player in the biotechnology arena, making strides in immunotherapy. The company's dedication to research and development reflects its commitment to turning scientific ideas into viable health solutions.
Frequently Asked Questions
What is the main goal of the Abzena and Mabqi partnership?
The partnership aims to provide a comprehensive and streamlined process for drug development, integrating antibody discovery with advanced manufacturing services.
How will this collaboration benefit biopharma companies?
By combining expertise and resources, biopharma companies can expect improved efficiency and faster timelines in bringing therapies to market.
What types of services will be available through this partnership?
The partnership offers a range of services, including antibody discovery, cell line development, and GMP manufacturing, tailored to client needs.
Who are the key leaders involved in this partnership?
Campbell Bunce from Abzena and Sylvain Yon from Mabqi are the primary leaders, emphasizing the innovative nature of their collaboration.
What sets Abzena and Mabqi apart in their respective fields?
Both companies bring distinct strengths, focused on scientific excellence and innovation, making them leaders in their areas of expertise.
